6 research outputs found
PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
The protein tyrosine phosphatase SHP2 activates oncogenic pathways downstream of most receptor tyrosine kinases (RTK) and has been implicated in various cancer types, including the highly aggressive subtype of triple-negative breast cancer (TNBC). Although allosteric inhibitors of SHP2 have been developed and are currently being evaluated in clinical trials, neither the mechanisms of the resistance to these agents, nor the means to circumvent such resistance have been clearly defined. The PI3K signaling pathway is also hyperactivated in breast cancer and contributes to resistance to anticancer therapies. When PI3K is inhibited, resistance also develops for example via activation of RTKs. We therefore assessed the effect of targeting PI3K and SHP2 alone or in combination in preclinical models of metastatic TNBC. In addition to the beneficial inhibitory effects of SHP2 alone, dual PI3K/SHP2 treatment decreased primary tumor growth synergistically, blocked the formation of lung metastases, and increased survival in preclinical models. Mechanistically, transcriptome and phospho-proteome analyses revealed that resistance to SHP2 inhibition is mediated by PDGFRβ-evoked activation of PI3K signaling. Altogether, our data provide a rationale for co-targeting of SHP2 and PI3K in metastatic TNBC
A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer
10.18632/oncotarget.14563Oncotarget8711530-1154
Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer
Aberrant activation of epithelial-mesenchymal transition (EMT) in carcinoma cells
contributes to increased migration and invasion, metastasis, drug resistance,
and tumor-initiating capacity. EMT is not always a binary process; rather, cells
may exhibit a hybrid epithelial/mesenchymal (E/M) phenotype. ZEB1—a key
transcription factor driving EMT—can both induce and maintain a
mesenchymal phenotype. Recent studies have identified two novel autocrine
feedback loops utilizing epithelial splicing regulatory protein 1 (ESRP1),
hyaluronic acid synthase 2 (HAS2), and CD44 which maintain high levels of ZEB1.
However, how the crosstalk between these feedback loops alters the dynamics of
epithelial-hybrid-mesenchymal transition remains elusive. Here, using an
integrated theoretical-experimental framework, we identify that these feedback
loops can enable cells to stably maintain a hybrid E/M phenotype. Moreover,
computational analysis identifies the regulation of ESRP1 as a crucial node, a
prediction that is validated by experiments showing that knockdown of ESRP1 in
stable hybrid E/M H1975 cells drives EMT. Finally, in multiple breast cancer
datasets, high levels of ESRP1, ESRP1/HAS2, and ESRP1/ZEB1 correlate with poor
prognosis, supporting the relevance of ZEB1/ESRP1 and ZEB1/HAS2 axes in tumor
progression. Together, our results unravel how these interconnected feedback
loops act in concert to regulate ZEB1 levels and to drive the dynamics of
epithelial-hybrid-mesenchymal transition
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma
A disintegrin and a metalloprotease (ADAM)‐9 is a metzincin cell‐surface protease with strongly elevated expression in solid tumors, including pancreatic ductal adenocarcinoma (PDAC). In this study, we performed immunohistochemistry (IHC) of a tissue microarray (TMA) to examine the expression of ADAM9 in a cohort of >100 clinically annotated PDAC cases. We report that ADAM9 is prominently expressed by PDAC tumor cells, and increased ADAM9 expression levels correlate with poor tumor grading (P = 0.027) and the presence of vasculature invasion (P = 0.017). We employed gene expression silencing to generate a loss‐of‐function system for ADAM9 in two established PDAC cell lines. In vitro analysis showed that loss of ADAM9 does not impede cellular proliferation and invasiveness in basement membrane. However, ADAM9 plays a crucial role in mediating cell migration and adhesion to extracellular matrix substrates such as fibronectin, tenascin, and vitronectin. This effect appears to depend on its catalytic activity. In addition, ADAM9 facilitates anchorage‐independent growth. In AsPC1 cells, but not in MiaPaCa‐2 cells, we noted a pronounced yet heterogeneous impact of ADAM9 on the abundance of various integrins, a process that we characterized as post‐translational regulation. Sprout formation of human umbilical vein endothelial cells (HUVECs) is promoted by ADAM9, as examined by transfer of cancer cell conditioned medium; this finding further supports a pro‐angiogenic role of ADAM9 expressed by PDAC cancer cells. Immunoblotting analysis of cancer cell conditioned medium highlighted that ADAM9 regulates the levels of angiogenic factors, including shed heparin‐binding EGF‐like growth factor (HB‐EGF). Finally, we carried out orthotopic seeding of either wild‐type AsPC‐1 cells or AsPC‐1 cells with silenced ADAM9 expression into murine pancreas. In this in vivo setting, ADAM9 was also found to foster angiogenesis without an impact on tumor cell proliferation. In summary, our results characterize ADAM9 as an important regulator in PDAC tumor biology with a strong pro‐angiogenic impact
ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer
A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor α (ERα), and its high cellular plasticity results in greater aggressiveness and poorer prognosis than other subtypes. Whether plasticity itself represents a potential vulnerability of cancer cells is not clear. However, we show here that cancer cell plasticity can be exploited to differentiate triple-negative breast cancer (TNBC). Using a high-throughput imaging-based reporter drug screen with 9 501 compounds, we have identified three polo-like kinase 1 (PLK1) inhibitors as major inducers of ERα protein expression and downstream activity in TNBC cells. PLK1 inhibition upregulates a cell differentiation program characterized by increased DNA damage, mitotic arrest, and ultimately cell death. Furthermore, cells surviving PLK1 inhibition have decreased tumorigenic potential, and targeting PLK1 in already established tumours reduces tumour growth both in cell line- and patient-derived xenograft models. In addition, the upregulation of genes upon PLK1 inhibition correlates with their expression in normal breast tissue and with better overall survival in breast cancer patients. Our results indicate that differentiation therapy based on PLK1 inhibition is a potential alternative strategy to treat TNBC